Los Angeles Capital Management LLC Has $1.46 Million Stock Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Los Angeles Capital Management LLC lowered its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 18.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 271,262 shares of the biotechnology company’s stock after selling 63,407 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Aldeyra Therapeutics were worth $1,462,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ALDX. The Manufacturers Life Insurance Company increased its holdings in shares of Aldeyra Therapeutics by 14.4% in the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 2,729 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Aldeyra Therapeutics by 7.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock worth $158,000 after buying an additional 3,446 shares during the period. Providence Wealth Advisors LLC lifted its stake in Aldeyra Therapeutics by 16.3% in the second quarter. Providence Wealth Advisors LLC now owns 25,000 shares of the biotechnology company’s stock valued at $84,000 after buying an additional 3,500 shares in the last quarter. Laidlaw Wealth Management LLC boosted its holdings in shares of Aldeyra Therapeutics by 32.6% in the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 4,150 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of Aldeyra Therapeutics by 23.4% during the first quarter. BNP Paribas Financial Markets now owns 25,278 shares of the biotechnology company’s stock worth $83,000 after acquiring an additional 4,797 shares in the last quarter. Institutional investors own 59.71% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research report on Friday, August 9th.

Aldeyra Therapeutics Trading Down 3.2 %

NASDAQ ALDX opened at $4.27 on Friday. Aldeyra Therapeutics, Inc has a 52 week low of $2.43 and a 52 week high of $6.55. The stock’s 50 day moving average price is $5.53 and its two-hundred day moving average price is $4.60. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, hitting the consensus estimate of ($0.25). As a group, research analysts forecast that Aldeyra Therapeutics, Inc will post -0.48 earnings per share for the current year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.